Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000351

Drug Information
NamePazopanib
SynonymsPazopanib; CID10113978; GW-786034; I09-0358; 790713-33-6; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonami; GW786034; 444731-52-6; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; AKOS005145819; UNII-7RN5DR86CK; ST51053493; CHEMBL477772; MolPort-006-827-156; Votrient; GW 786034; Kinome_3790; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; Pazopanib [INN]; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-
CompanyGSK
IndicationAdvanced / metastatic renal cancer
[ICD9: 189   ICD10: C64]
Phase III    [1]
Solid tumours, NSCLC
[ICD9: 140-199, 162, 210-229   ICD10: C00-C75, C33, C34, C7A, C7B, D10-D36, D3A]
Phase II completed    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20
(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,2
2,29,30)(H,23,24,25)
InChIKeyCUIHSIWYWATEQL-UHFFFAOYSA-N
Canonical SMILESCC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 444731-52-6
FormulaC21H24ClN7O2S
PubChem Compound IDCID 10113978.
PubChem Substance IDSID 15102663.
SuperDrug ATC IDL01XE11
ClinicalTrials.govNCT00334282;
NCT00367679;
TargetMast/stem cell growth factor receptorInhibitor[2][3][4]
Mast/stem cell growth factor receptorMultitarget[2][3][4]
Platelet-derived growth factor receptorInhibitor[2][3][4]
Platelet-derived growth factor receptorMultitarget[2][3][4]
Vascular endothelial growth factor receptor 2Inhibitor[2][3][4]
Vascular endothelial growth factor receptor 2Multitarget[2][3][4]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 3GSK. Product Development Pipeline. February 2009. To Reference
Ref 4Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543